EUVIMEDEUVIMED entdecken
Open Access

Catalytic Degraders Effectively Address Kinase Site Mutations in EML4-ALK Oncogenic Fusions

Yang Gao, Baishan Jiang iD, Hellen Kim, Matthew J Berberich iD, Jianwei Che, Katherine A Donovan iD, John M Hatcher, Fidel Huerta, Nicholas P Kwiatkowski, Yingpeng Liu iD, Peter P Liuni, Rebecca J Metivier iD und 6 weitere

Journal of Medicinal Chemistry · 27.04.2023 · 66 (8) · 5524-5535

DOI: 10.1021/acs.jmedchem.2c01864 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 10.04.2023. Verfasst von Yang Gao und 17 weiteren Autor:innen. Beteiligte Einrichtung: Center for Protein Degradation, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States. Hauptthemen laut MEDLINE: Antineoplastic Agents, Lung Neoplasms. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heterobifunctional degraders, known as proteolysis targeting chimeras (PROTACs), theoretically possess a catalytic mode-of-action, yet few studies have either confirmed or exploited this potential advantage of event-driven pharmacology. Degraders of oncogenic EML4-ALK fusions were developed by conjugating ALK inhibitors to cereblon ligands. Simultaneous optimization of pharmacology and compound properties using ternary complex modeling and physicochemical considerations yielded multiple catalytic degraders that were more resilient to clinically relevant ATP-binding site mutations than kinase inhibitor drugs. Our strategy culminated in the design of the orally bioavailable derivative CPD-1224 that avoided hemolysis (a feature of detergent-like PROTACs), degraded the otherwise recalcitrant mutant L1196M/G1202R in vivo, and commensurately slowed tumor growth, while the third generation ALK inhibitor drug lorlatinib had no effect. These results validate our original therapeutic hypothesis by exemplifying opportunities for catalytic degraders to proactively address binding site resistant mutations in cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsLung NeoplasmsHumansAnaplastic Lymphoma KinaseReceptor Protein-Tyrosine KinasesProtein Kinase InhibitorsMutationDrug Resistance, NeoplasmOncogene Proteins, Fusion

Substanzen

Anaplastic Lymphoma KinaseAntineoplastic AgentsReceptor Protein-Tyrosine KinasesProtein Kinase InhibitorsEML4-ALK fusion protein, humanOncogene Proteins, Fusion

Autor:innen und Institutionen

  • Center for Protein Degradation, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.
  • Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02215, United States.
  • Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.
  • Department of Chemical and Systems Biology, ChEM-H, Stanford Cancer Institute, School of Medicine, Stanford University, Stanford, California 94305, United States.

ORCID-Profile: Baishan Jiang, Matthew J Berberich, Katherine A Donovan, Yingpeng Liu, Rebecca J Metivier, Radosław P Nowak, Eric S Fischer, Nathanael S Gray, Lyn H Jones

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Gao, Y., Jiang, B., Kim, H., Berberich, M. J., Che, J., Donovan, K. A., Hatcher, J. M., Huerta, F., Kwiatkowski, N. P., Liu, Y., Liuni, P. P., Metivier, R. J., Murali, V. K., Nowak, R. P., Zhang, T., Fischer, E. S., Gray, N. S., & Jones, L. H. (2023). Catalytic Degraders Effectively Address Kinase Site Mutations in EML4-ALK Oncogenic Fusions. Journal of Medicinal Chemistry, 66(8), 5524-5535. https://doi.org/10.1021/acs.jmedchem.2c01864

Vancouver

Gao Y, Jiang B, Kim H, Berberich MJ, Che J, Donovan KA, et al. Catalytic Degraders Effectively Address Kinase Site Mutations in EML4-ALK Oncogenic Fusions. Journal of Medicinal Chemistry. 2023;66(8):5524-5535. doi:10.1021/acs.jmedchem.2c01864

BibTeX
@article{Gao2023,
  author = {Gao, Yang and Jiang, Baishan and Kim, Hellen and Berberich, Matthew J and Che, Jianwei and Donovan, Katherine A and Hatcher, John M and Huerta, Fidel and Kwiatkowski, Nicholas P and Liu, Yingpeng and Liuni, Peter P and Metivier, Rebecca J and Murali, Vineeth K and Nowak, Radosław P and Zhang, Tinghu and Fischer, Eric S and Gray, Nathanael S and Jones, Lyn H},
  title = {Catalytic Degraders Effectively Address Kinase Site Mutations in EML4-ALK Oncogenic Fusions},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  volume = {66},
  number = {8},
  pages = {5524--5535},
  doi = {10.1021/acs.jmedchem.2c01864}
}
Kostenlos starten →